If you take two different medications for two different reasons, here's a sobering thought: your doctor may not fully understand what happens when they're combined, because drug interactions are incredibly hard to study. In this fascinating and accessible talk, Russ Altman shows how doctors are studying unexpected drug interactions using a surprising resource: search engine queries.
The pharmaceutical industry is constantly battling the same issue when trying to discover drugs; the process is timely, expensive and usually unsuccessful. Pharma companies are trying to speed up the procedure to make it more accurate and minimise drug leads which are likely to fail further on in the drug development process. Consequently, the event will focus on key developments in this very industry.
The global pharmacovigilance (PV) market is expected to reach USD 10.27 billion by 2025. The market is expected to witness growth at 13.1% CAGR owing to Increasing incidence of ADR is key driver for the growth of pharmacovigilance market. As of 2015, the U.S. FDA received approximately 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the potential demand for implementing safety and pharmacovigilance services over the forecast period.15th Annual Pharmacovigilance 2018 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.
This webinar is focused on understanding the requirements for Good Pharmacovigilance Practices that are effective in the European Union since July 2012. The New Guidance on Good Pharmacovigilance Practices (GVP) has been updated by Module, of which the first seven Modules have been disclosed for public consultation.
There is a very real increase in the mandated frequency of real-time requests by the FDA for post-marketing surveillance and actual Phase IV trials and it seems that no one is well prepared. It is now reasonable to expect that the Sponsor's should include Post-approval trials as part of the development of any new Investigational Medicinal Product (IMP). Investigators, as well as all site staff, must know how to assess Pre and Post market ADR's as safety of the public is in the balance.